Showing 76–100 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Ali SH, Shakir S, Shaikh UA, Khalid M, Jawed M, et al.
…bal cause of death. While primary Bacillus Calmette-Guérin (BCG) vaccination offers protection in children, the role of BCG revaccination in adults remains unclear. This study evaluated the efficacy, immunogenicity, and safety of BCG revaccination against TB. A comprehensive lite…
Syed Hassan Ali, Shanza Shakir, Umais Ahmed Shaikh, Maryam Khalid, Maria Jawed, et al.
…ause of death. While primary Bacillus Calmette-Guérin (BCG) vaccination offers protection in children, the role of BCG revaccination in adults remains unclear. This study evaluated the efficacy, immunogenicity, and safety of BCG revaccination against TB. A comprehensive lite…
Angelique Kany Kany Luabeya, Virginie Rozot, Claire Imbratta, Frances Ratangee, Justin Shenje, et al.
**BACKGROUND:** An effective adult vaccine is needed to control tuberculosis. We evaluated the safety and immunogenicity of a live-attenuated Mycobacterium tuberculosis vaccine (MTBVAC). **METHODS:** This single-centre, phase 1b-2a, double-blind, dose-escalation, randomised cont…
Gabriela Sadigurschi, Maria Cristina Caetano Kuschnir, Ewerton Alves Portela Dos Santos, Bruno Rangel Antunes da Silva, Celia Menezes Cruz Marques, et al.
…den. Currently, the neonatal Bacillus Calmette-Guérin (BCG) is the only vaccine against TB and offers significant efficacy against disseminated and meningeal disease in children. However, BCG has a limited efficacy in preventing adult-type cavitary TB, reinforcing the need f…
Korompis M, De Voss CJ, Li S, Richard A, Almujri SS, et al.
BCG remains the only licensed vaccine for tuberculosis (TB), but its efficacy wanes over time. Subunit vaccines, aim to improve BCG immunity and protection, by inducing responses to a few mycobacterial antigens delivered with a specific platform. Since the platform shapes the imm…
Ahmed Mohamed Dirie, Nor Afiah Mohd Zulkefli, Salmiah Md Said, Ahmed Zaid Fatah Azman, Kassim Abdi Jimale, et al.
… 12 to 23 months receive the Bacillus Calmette-Guérin (BCG) vaccine in Somalia, which helps prevent TB-disseminated diseases. Among the major factors that contribute to poor BCG uptake and TB prevention practices are the lack of maternal knowledge, negative attitude, and poo…
Ferluga J, Yasmin H, Bhakta S, Kishore U
…mmunometabolism, and other environmental factors. Till now, BCG is the only vaccine available to prevent TB but the protection rendered by BCG against pulmonary TB is not uniform. To deliver a vaccine which can give consistent protection against TB is a great challenge with risin…
Helen McShane
…aring two different strains of the Bacille Calmette-Guérin (BCG) vaccine at standard and high dose. Currently, to assess vaccine efficacy against tuberculosis (TB) there is no alternative to large randomized controlled trials. These efficacy trials for novel TB vaccines are diff…
Ginsberg AM
…s (TB) is the leading infectious killer globally and new TB vaccines will be crucial to ending the epidemic. Since the introduction in 1921 of the only currently licensed TB vaccine, BCG, very few novel vaccine candidates or strategies have advanced into clinical efficacy trials.…
Mourits VP, Koeken VACM, de Bree LCJ, Moorlag SJCFM, Chu WC, et al.
BCG vaccination protects not only against tuberculosis but also against heterologous infections. This effect differs between individuals, yet the factors responsible for this variation are unknown. BCG-induced nonspecific protection is, at least partially, mediated by innate immu…
Stephen Gordon, MD
Despite tremendous efforts, an effective tuberculosis (TB) vaccine remains elusive. TB continues to infect and kill many. In 2021, TB infected more than 10 million and killed 1.6 million people. To date, the M.bovis bacille Calmette Guerin (BCG) is the only licensed vaccine again…
Trim Lajqi, Natascha Köstlin‐Gille, Christian Gille
… innate immune cells to exhibit rapid action with increased efficacy against subsequent infections. Here we will discuss the role of TRIM and its implications for infectious diseases in childhood. The Concept of Trained Innate Memory Although lacking an adaptive immune system, pl…
Wang R, Fan X, Xu D, Li M, Zhao X, et al.
Bacillus Calmette-Guérin (BCG) is the only widely used prophylactic tuberculosis (TB) vaccine that can prevent severe TB in infants. However, it provides poor protection in adults, and therefore, there is ongoing research into new TB vaccines and immunization strategies with more…
Nisa A, Counoupas C, Pinto R, Britton WJ, Triccas JA
Mycobacterium bovis Bacillus Calmette-Guérin (BCG) is the only approved vaccine against tuberculosis (TB). However, its efficacy in preventing pulmonary TB in adults is limited. Despite its variable efficacy, BCG offers a number of unique and beneficial characteristics, which mak…
Mao LR, Du JP, Wang XC, Xu LF, Zhang YP, et al.
…dormant Mycobacterium tuberculosis is an important cause of adult tuberculosis (TB) transmission. According to the interaction mechanism between M. tuberculosis and the host, the latency antigen Rv0572c and region of difference 9 (RD9) antigen Rv3621c were selected in this study …
Gregor Nosan, Andreja Cerkvenik Škafar
…coring the continued role of Bacillus Calmette-Guérin (BCG) vaccination. BCG vaccination provides strong protection against severe forms of TB in infancy, though its efficacy against pulmonary disease in adolescents and adults is modest. However, the BCG vaccine carries a ri…
Carine Rouanet, Anne-Sophie Debrie, Stephane Cauchi, Nathalie Mielcarek
…ency. BPZE1 is the most advanced, next-generation pertussis vaccine undergoing clinical evaluation in children and adults. We investigated the feasibility of co-administering BPZE1 and Bacillus Calmette-Guerin (BCG), the most widely used tuberculosis vaccine worldwide. We showed …
Heijmenberg I, Husain A, Sathkumara HD, Muruganandah V, Seifert J, et al.
…ng infectious cause of death globally. The only licensed TB vaccine, Bacille Calmette-Guérin (BCG), has low efficacy against TB in adults and is not recommended in people with impaired immunity. The incorporation of the Mycobacterium tuberculosis (Mtb) secretion system ESX-1 into…
Soo-Min Kim, Jin-Seung Yun, EunJung Shin, Jinhee Lee, You-Jin Kim, et al.
…al health challenge, and the Bacillus Calmette-Guérin (BCG) vaccine has limited efficacy against adult pulmonary disease. Protein subunit vaccines are a promising alternative but require strong adjuvants to induce cell-mediated immunity. Synthetic agonists targeting toll-lik…
Moonsu Lee, Dohyeon Jeong, Kiyoung Yoon, Juyoung Jin, Yong Woo Back, et al.
…023, despite the century-old Bacillus Calmette-Guérin (BCG) vaccine. BCG's protective efficacy diminishes over time, especially against pulmonary TB in adults. This study evaluates ethanol-inactivated() delivered via Microneedle Array Patches (MAPs) as a novel booster strate…
Khanna M, Rady H, Dai G, Ramsay AJ
Bacille-Calmette-Guerin (BCG) has variable efficacy as an adult tuberculosis (TB) vaccine but can reduce the incidence and severity of TB infection in humans. We have engineered modified vaccinia Ankara (MVA) strain vaccine constructs to express the secreted mycobacterial protein…
Professor Helen McShane, Professor Paul Moss
…linical challenge trial primarily to evaluate the safety of BCG challenge administered by the aerosol inhaled route in healthy, BCG naive UK adults. The trial will also look to evaluate and compare the amount of BCG recovered from the lungs and from the skin, following challenge …
Zhu B, Dockrell HM, Ottenhoff THM, Evans TG, Zhang Y
…serious disease around the world. Bacillus Calmette-Guérin (BCG) is the only TB vaccine licensed for use in human beings, and is effective in protecting infants and children against severe miliary and meningeal TB. However, BCG's protective efficacy is variable in adults. Novel T…
Kee Woong Kwon, Hongmin Kim, Hagyu Kim, Roland Brosch, Sung Jae Shin
Although Bacille Calmette-Guérin (BCG) protects children against disseminated tuberculosis (TB), its limited efficacy against adult pulmonary TB underscores the need for improved vaccination strategies. We previously developed a recombinant BCG strain expressing the ESX-1 ty…
Pelzer PT, Stuck L, Martinez L, Richards AS, Acuña-Villaorduña C, et al.
Background Tuberculosis vaccine trials using disease as the primary endpoint are large, time consuming, and expensive. An earlier immunological measure of the protection against disease would accelerate tuberculosis vaccine development. We aimed to assess whether the effectivenes…